Zacks Research Weighs in on Ironwood Pharmaceuticals, Inc.’s Q4 2024 Earnings (NASDAQ:IRWD)

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWDFree Report) – Equities research analysts at Zacks Research increased their Q4 2024 earnings estimates for Ironwood Pharmaceuticals in a report released on Wednesday, March 20th. Zacks Research analyst R. Department now expects that the biotechnology company will post earnings per share of $0.10 for the quarter, up from their previous forecast of $0.09. The consensus estimate for Ironwood Pharmaceuticals’ current full-year earnings is $0.70 per share. Zacks Research also issued estimates for Ironwood Pharmaceuticals’ Q3 2025 earnings at $0.21 EPS, Q4 2025 earnings at $0.21 EPS and FY2025 earnings at $0.84 EPS.

Several other equities research analysts also recently weighed in on IRWD. Piper Sandler raised their target price on shares of Ironwood Pharmaceuticals from $20.00 to $21.00 and gave the company an “overweight” rating in a research note on Friday, February 16th. StockNews.com downgraded shares of Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, March 14th. Craig Hallum started coverage on shares of Ironwood Pharmaceuticals in a research note on Wednesday, January 17th. They issued a “buy” rating and a $21.00 target price for the company. Finally, Wells Fargo & Company lowered their target price on shares of Ironwood Pharmaceuticals from $20.00 to $14.00 and set an “overweight” rating for the company in a research note on Friday, March 1st. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $19.80.

View Our Latest Report on IRWD

Ironwood Pharmaceuticals Stock Down 3.9 %

Shares of IRWD stock opened at $8.68 on Thursday. The firm has a market cap of $1.36 billion, a price-to-earnings ratio of -1.33 and a beta of 0.56. The company’s 50 day moving average is $12.42 and its 200 day moving average is $10.82. Ironwood Pharmaceuticals has a 52-week low of $8.07 and a 52-week high of $15.70.

Insider Transactions at Ironwood Pharmaceuticals

In other news, CEO Thomas A. Mccourt sold 177,164 shares of Ironwood Pharmaceuticals stock in a transaction on Monday, February 12th. The shares were sold at an average price of $15.24, for a total transaction of $2,699,979.36. Following the completion of the sale, the chief executive officer now directly owns 832,774 shares in the company, valued at $12,691,475.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In related news, insider Minardo John sold 47,380 shares of the business’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $15.24, for a total transaction of $722,071.20. Following the completion of the transaction, the insider now directly owns 224,796 shares in the company, valued at $3,425,891.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Thomas A. Mccourt sold 177,164 shares of the business’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $15.24, for a total transaction of $2,699,979.36. Following the transaction, the chief executive officer now owns 832,774 shares of the company’s stock, valued at $12,691,475.76. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 273,008 shares of company stock worth $4,160,642. Company insiders own 13.10% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in IRWD. Voya Investment Management LLC increased its holdings in Ironwood Pharmaceuticals by 0.6% in the fourth quarter. Voya Investment Management LLC now owns 116,057 shares of the biotechnology company’s stock valued at $1,328,000 after buying an additional 726 shares in the last quarter. Old West Investment Management LLC increased its holdings in Ironwood Pharmaceuticals by 1.4% in the fourth quarter. Old West Investment Management LLC now owns 56,921 shares of the biotechnology company’s stock valued at $651,000 after buying an additional 761 shares in the last quarter. Signaturefd LLC increased its holdings in Ironwood Pharmaceuticals by 61.4% in the fourth quarter. Signaturefd LLC now owns 2,160 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 822 shares in the last quarter. Cetera Advisor Networks LLC increased its holdings in Ironwood Pharmaceuticals by 8.8% in the first quarter. Cetera Advisor Networks LLC now owns 11,021 shares of the biotechnology company’s stock valued at $139,000 after buying an additional 893 shares in the last quarter. Finally, Virtus ETF Advisers LLC increased its holdings in Ironwood Pharmaceuticals by 3.5% in the fourth quarter. Virtus ETF Advisers LLC now owns 28,489 shares of the biotechnology company’s stock valued at $326,000 after buying an additional 951 shares in the last quarter.

Ironwood Pharmaceuticals Company Profile

(Get Free Report)

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.

Read More

Earnings History and Estimates for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.